消异方治疗子宫内膜异位症的疗效观察及安全性分析

目的]探讨消异方治疗子宫内膜异位症的临床疗效及其安全性。方法]将60例确诊的子宫内膜异位症患者随机分为两组,治疗组和对照组,分别给予消异方胶囊和孕三烯酮胶囊口服。采用视觉模拟评分法(VAS)评价痛经评分,经阴道超声测量异位囊肿直径和子宫动脉血流阻力指数(RI),酶联免疫吸附(ELISA)法测定血清CA125水平,并观察计算痤疮、肝功异常、阴道点滴出血、血脂异常及体质量增加等不良反应的发生率,比较两组治疗前后上述指标的差异。结果]两组治疗后VAS疼痛积分、异位囊肿直径、血清CA125水平均明显低于治疗前(P0.01),但变化的程度差异无统计学意义(P0.05),两组患者的总有效率差异无统计学意义(P0.05),治疗组治疗后子宫动脉血流的阻力指数显著降低(P0.05);治疗组不良反应发生率明显低于对照组(P0.05)。结论]临床应用消异方治疗子宫内膜异位症与孕三烯酮胶囊疗效相当,且安全性更高。

Efficacy and safety of Xiaoyi formula in the treatment of endometriosis

Objective] To observe the efficacy and safety of Xiaoyi formula in treating endometriosis.Methods] The 60 patients diagnosed as endometriosis were randomly divided into two groups,30 cases of treatment group administered capsule of Xiaoyi formula and 30 cases of control group given gestrinone. The pain score was evaluated with Visual analogue scale (VAS). The size of endometrial cysts and resistance indexes (RI) of uterine arteries were evaluated with ultrasonography. The serum CA125 levels was determined by ELISA. The incidence of adverse reactions, which included to acne, dysfunction of liver, colporrhagia, dyslipidemia and weight gain, was also observed. The differences of these indicators were compared before and after treatment.Results] The VAS scores, size of endometrial cysts as well as CA125 levels in both group decreased significantly,but the differences of the changes were not significant (P>0.05). The differences of the total effects rates were not statistically significant (P>0.05). RI in treatment group decreased significantly (P<0.05). The incidence adverse effects in treatment group were significantly lower than the control group (P<0.05).Conclusion] Clinically, Xiaoyi formula is as effective as gestrinone capsules, and it is safer than gestrinone capsules.